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As leishmanioses são doenças parasitárias que têm como agente etiológico um 
protozoário do género Leishmania. São transmitidas através da picada de insetos 
vetores, pertencentes à família Phlebotominae. É considerada um problema de saúde 
pública em vários países, e dependendo da espécie infetante origina diversas 
manifestações clínicas. O sistema imunitário é um importante componente do nosso 
organismo que tem a capacidade de identificar, inativar e eliminar os agentes 
patogénicos. Contudo, após ser fagocitado por macrófagos (MØ) Leishmania sobrevive, 
multiplica-se e estabelece uma infeção crónica no hospedeiro mamífero, subvertendo a 
atividade desta célula da imunidade inata que é também responsável pela apresentação 
antigénica e pela ligação à imunidade adquirida. Deste modo, é importante explorar a 
atividade macrofágica na presença de diferentes estirpes de Leishmania spp., tendo em 
vista a identificação de novos alvos profiláticos e terapêuticos, sobretudo que 
possibilitem novas soluções para colmatar a resistência aos fármacos antileishmania. No 
presente estudo foram avaliadas as taxas de infeção em macrófagos humanos expostos a 
promastigotas de L. infantum e de especies cutâneas de Leishmania. Adicionalmente, 
outros parâmetros importantes para a caracterização destas infeções, nomeadamente a 
produção do óxido nítrico (NO), análiseda libertação de armadilhas extracelulares por 
macrófagos (MET) e a capacidade de apresentarem antigénios através de moléculas do 
complexo maior de histocompatibilidade (MHC) foram investigados. Foi verificado que 
as espécies cutâneas originaram maiores taxas de infeção face à espécie visceral, o que 
conduziu a uma maior intensidade de infeção dos MØ. Foi também possível descrever 
pela primeira vez a libertação de MET na presença de L. infantum, ainda que 
aparentemente de uma forma controlada, e seguir o percurso da histona H1 desde o 
núcleo até ao espaço extracelular. As espécies de Leishmania analisadas induziram a 




 e o aumento  destas moléculas na 
superfície dos MØ, indicando a existência de apresentação antigénica e a possibilidade 
de ocorrer a estimulação quer dos linfócitos T helper quer dos linfócitos T citotóxicos. 
Apesar de o MØ dispor de um conjunto de mecanismos de controlo directo da infeção e 
de poder activar a resposta imune mediada por células, o parasita parece modelar estes 
mecanismos, provavelmente conduzindo a seleção dos parasitas mais virulentos, 
capazes de estabelecer a infeção e causar doença do hospedeiro  
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Leishmaniasis is a parasitic disease caused by an intracellular protozoan of genus 
Leishmania and is transmitted by the bite of an insect vector, the phlebotomine sand fly. 
It is considered a Public Health problem in numerous countries and depending on the 
infecting species, the disease can present multiple clinical manifestations; cutaneous, 
visceral and mucocutaneous leishmaniasis. Cutaneous leishmaniasis can be produced by 
L. amazonensis, L. shawi and L. guyanensis among many other species. Leishmania 
infantum is the agent responsible for zoonotic visceral leishmaniasis, considered the 
most severe form that can be fatal if not treated. The mammal immune response is an 
important barrier that can prevent the establishment of a long-lasting chronic infection. 
Macrophages (MØ) play an important role being phagocytic and antigenic presenting 
cells, and moreover the definitive host cells of Leishmania parasite. It is important to 
analyze the activity of human MØ in presence of visceral and cutaneous species of 
Leishmania spp. in order to better understand the strategies used by the parasite to 
subvert MØ mechanisms of defense. This information is relevant to find new targets for 
the development of prophylactic and therapeutic tools, mainly the establishment of new 
anti-Leishmania therapeutics, since drug resistance has been reported. Having that in 
mind, the behavior of human MØ exposed to Leishmania promastigotes was 
investigated. Infection levels, oxidative burst, release of extracellular traps (MET) and 
antigenic presentation by major histocompatibility complex (MHC) were in vitro 
evaluated. It was found that the cutaneous species have a higher rate of infection, which 
drive a higher infection intensity. It was also possible to describe for the first time that 
L. infantum parasites induce the release of MET, although apparently in a controlled 
way, and to follow the histone H1 from the nucleus to the extracellular environment. 
The four species of Leishmania induced the expansion of MHCI
+
MØ and of 
MHCII
+
MØ subsets as well as the increase of these molecules at MØ surface, pointing 
towards the existence of antigenic presentation and the possibility of stimulation of both 
helper and cytotoxic T lymphocytes. Although MØ has a set of mechanisms that can 
control the infection and be able to induce the activation of cell-mediated immune 
response, the parasite seems to negatively modulate these mechanisms, probably 
directing the selection of the most virulent parasites able to establish infection in the 
host and promote disease development. 
 
Keywords: Macrophages, Leishmania spp., Macrophage extracellular traps; Molecules 







Leishmaniasis is a parasitic disease caused by the intracellular protozoan of genus 
Leishmania Ross, 1903 (Basano et al. 2004; Croft et al. 2006), order Kinetoplastida and 
family Trypanosomatidae. This parasite is transmitted by the bite of an insect vector, 
the phlebotomine sand fly (Andrade et al. 2007). At least 30 species of Leishmania are 
identified and 20 of them are pathogenic for humans (Banuls et al., 2007). 
Most species of Leishmania that cause human disease are zoonotic, meaning that 
animals are reservoirs of the parasite, such as the domestic dog and sylvatic animals, 
including rodents, monkeys, sloths and foxes. However, a few species give origin to 
anthroponotic diseases as is the case of L. donovani that is characteristically transmitted 
man-to-man through the sand fly bite.  
Leishmaniasis is spreading over the Mediterranean to tropic and subtropic regions 
worldwide. The presence or absence of parasite species is determined by the geographic 




The estimated number of new cases of leishmaniasis per year is more than 2 million, 
according with WHO.  A total of 98 countries of Latin America, Africa, Southern 
Europe and Asia reported human cases of leishmaniasis. However, the worldwide 
incidence and prevalence still are difficult to establish since this parasitic disease is not 
an obligatory reported in every endemic country. In fact, only 33 of 98 endemic 
countries present regular reports specifying the annual number of leishmaniasis cases 
diagnosed (Desjeux, 2004; Pigott et al. 2014). 
Depending on the infecting species, the disease can present multiple clinical 
manifestations (Desjeux and Alvar, 2003) that can be differentiated into three major 
clinical syndromes: visceral leishmaniasis (VL), which is also known as kala-azar 
(Desjeux, 1996; Murray, 2005; Chappuis, 2007), cutaneous leishmaniasis (CL) and 




1.1.1. Visceral Leishmaniasis 
Visceral leishmaniasis (VL) is considered the most severe form that can be fatal if not 
treated. According to WHO (2015), more than 90% of cases occur mainly in 
Bangladesh (600 new cases), Brazil, Ethiopia, India, South Sudan and Sudan. In the Old 
World (Europe, Africa and Asia), L. donovani and L. infantum are VL etiologic agents 
(Berman, 1997). The main sand fly vector responsible for the transmission of 
Leishmania spp. belongs to the genus Phlebotomus (Killick-Kendrick and Rioux, 2002). 
The typical symptoms are prolonged intermittent fever, abdominal distension, with 
splenomegaly and hepatomegaly, lymphadenopathy, decreased appetite, weight loss and 
in many cases, signs of chronic kidney disease. Some cases that remain asymptomatic 
or subclinical may resolve spontaneously (Dawit et al., 2013; Farrar et al., 2014). 
 
1.1.2. Cutaneous Leishmaniasis 
Cutaneous leishmaniasis (CL) is the most common clinical form characterized by the 
presence of localized cutaneous lesions that, depending on the infecting species, can 
originate  lifelong scars. The self-healing scenario is also possible but in some cases it 
may take several months and some forms leave permanent lesions(Reithinger et al., 
2007). Countries like Afghanistan, Algeria, Brazil, Colombia, the Islamic Republic of 
Iran, Pakistan, Peru, Saudi Arabia and the Syrian Arab Republic are the most affected 
(WHO 2015).  
L. braziliensis, L. panamensis, L. guyanensis, L. shawi, L. peruviana, L. mexicana, L. 
amazonensis, L. venezuelensis,L. lainsoni, L. naiffi and L. lindenbergiof New World 
and, L. tropica, L. major and L. aethiopica of Old World are the species involved in 
CL(Ashford, 2000; Dedet and Pratlong, 2003; Reithinger et al., 2007). 
 
1.1.3. Mucocutaneous Leishmaniasis 
Mucocutaneous Leishmaniasis (MCL, also called espundia) usually refers to a 
metastatic cutaneous infection caused by the parasite spread to the naso-oropharyngeal 
mucosa. The majority of cases occurs in Bolivia, Brazil and Peru. 
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Although L. braziliensis is the species usually associated with MCL L.  panamensis, L.  
colombiensis, L. peruviana and, less often L. guyanensis can also cause MCL (Dedet 
and Pratlong, 2003). The initial manifestations are erythema and ulceration at the nares 
that if left untreated can spread, involving the nasal septum, and in some cases, the 
pharynx or larynx (Dawit et al., 2013.), which can lead to the partial or total destruction 
of mucous membranes, causing serious disability. 
1.2. The Parasite 
1.2.1. Morphology 
Leishmania is an eukaryote unicellular protozoan parasite that replicates by binary 
fission. This digenetic microorganism differentiates in two main morphological forms 
during its life cycle, the amastigote and the promastigote. 
Amastigotes are small, round to oval bodies not exhibiting an external flagellum. This 
intracellular obligatory parasitic form is found inside the mononuclear phagocytic cells 
of infected vertebrate hosts. 
Promastigote forms can be found in the midgut of the insect vector. These slender 
microorganisms are extracellular and present single anterior flagellum that confers 
motility (Figure 1.1). Furthermore, it is possible to differentiate two stages in 
promastigote development (Bates and Rogers, 2004). Procyclic promastigote which has 
an elongated shape, are bigger than amastigote and, usually have a shorter flagellum. 
This parasite form is not infectious, but is in constant replication. Metacyclic 
promastigotes present a short form, but have a long flagellum that can be two to three 
times longer than the cell body. This long flagellum confers to this highly infectious 




Figure 1.1. Life stages of Leishmania spp. Schematic representation of the amastigote (a) and 
promastigote (b) morphological forms. F - flagellum; B - flagelar pocket;  K- kinetoplast; RE- 




I.2.2. Life Cycle 
Leishmania spp. alternates between two morphological forms highly adapted to distinct 
environments.  Promastigote, that is in sintony with the midgut of the insect vector and 
amastigote, that is adjusted to live inside the phagolysosome of mammalian macrophage 
(MØ) (Rivas et al., 2004). 
The infection occurs when a female sand fly takes a blood meal in the vertebrate host 
and flagellate promastigotes gain access to the vertebrate skin. Then parasites are 
rapidly internalized by macrophages MØ. Once inside the cell they differentiate into 
amastigote, which replicates actively. The cycle is completed when another sand fly 
ingests parasitized MØ in a new meal. When inside the vector gut, amastigotes rapidly 
convert back into promastigotes (Carlsen et al., 2015). 
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Figure 1.2. The life cycle of Leishmania spp. Schematic representation of parasite life cycle in the 
mammalian (right) host and inside the vector (left). Adapted from CDC, 2016 and 
http://www.parasitologie.univ-montp1.fr/english_vers/en_leish2.htm# 
 
I.2.3. Vertebrate Host-parasite Interaction 
The invasion of the vertebrate host by Leishmania spp. involves several factors of the 
humoral and cellular immune system. Macrophages are the preferred target, but 
parasites can be found in other cells like neutrophils and dendritic cells (DCs) (Bogdan 
et al., 2000a; Feijó et al., 2016). 
It is important to have an effective immune response considering that Leishmania 
parasites are preferentially intracellular and it is expected that properly activated MØ 
kill the parasite. Amastigotes stay in the parasitophorous vacuoles that fuse with 
lysosomes rich in proteolytic enzymes, generating the phagolysosomes (Bogdan and 
Röllinghoff, 1998) that should promote parasite lysis. Furthermore, respiratory burst 
activity that includes the production of reactive nitrogen and oxygen species is one of 
the mechanisms used by phagocytes to destroy intruders (Murray and Nathan, 1999). 
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However, Leishmania has developed a set of strategies able to subvert MØ activity and 
resist to the host defense system. The parasite has a mechanism that allows protein 
kinase to phosphorylate components important to the lytic activity of complement, such 
as C3, C5 and C9 (Zambrano-Villa et al.,2002). This enzyme modifies other proteins by 
chemically adding phosphate groups, resulting in functional changes of the target 
protein. Inhibiting phagosome-lysosome fusion by the action of lipophosphoglycan 
(Desjardins and Descoteaux, 1997), parasites protect themselves from oxidative stress 
(Bogdan and Röllinghoff, 1999). Furthermore, amastigote forms are resistant to 
enzymes and acidic pH of the phagolysosome (Bogdan et al., 1990; Kima, 2007). 
Another way used by the parasite is to interfere with the immune mechanisms. This 
parasite difficult the crosstalk between MØ and T cell by avoiding the antigen 
presentation trough class I (MHCI) and class II (MHCII) molecules of major 
histocompatibility complex.  Consequently, interfering with antigen presentation the 
parasite prevent T cell activation, avoid the release of pro-inflammatory cytokines 
(Podinovskaia and Descoteaux, 2015) and, in some cases enhance the production of 
anti-inflammatory interleukin (IL)-4, the regulatory tumor growth factor (TGF)- and 
IL-10 (Bhattacharya and Ali, 2013). 
All these mechanisms keep infected MØ inactivated, resulting in increased host 
susceptibility to the parasite (Podinovskaia and Descoteaux, 2015). 
 
1.3. Immune Response 
The invasion of vertebrate host by Leishmania parasites causes a set of reactions 
involving all defense components of innate and acquired immunity. 
 
1.3.1 Innate Immune System 
After inoculation in the skin, the parasite has to face the cytotoxic action triggered by 
the innate immune response. It promotes an immediate robust and nonspecific immune 
response, which plays an important role in controlling or eliminating pathogenic 
invaders (Dunkelberger and Song, 2010). 
15 
 
The complement system consists of a wide range of proteins organized hierarchically in 
proteolytic cascades that can promote pathogen destruction or target the pathogen, 
directing its annihilation by effector cells (Sacks and Sher, 2002; Dunkelberger and 
Song, 2010). However, metacyclic promastigotes have mechanisms that allow them to 
block the lytic activity of the complement system. Furthermore, the parasite also can use 
the complement factors to facilitate MØ recognition and enhance promastigote 
phagocytosis (Brittingham and Mosser, 1996; Cunningham, 2002), subverting immune 
system function. Lypophosphoglycan (LPG), an abundant constituent of parasite 
surface, covering the entire organism, including the flagellum has an important role in 
the immune escape, preventing the insertion in the parasite membrane of the lytic 
complex of complement factors (membrane attack complex, MAC) (Sher, 2002; 
Dunkelberger and Song, 2010) avoiding its own destruction. 
Glycoprotein of 63kDa (gp63), a metalloprotease present in the surface of Leishmania 
parasites promotes the conversion of the complement factor C3b to its inactive form 
(iC3b). The presence of iC3b in parasite membrane enhances promastigote uptake by 
phagocytes (Brittingham and Mosser, 1996). 
Leishmania protein kinases also can phosphorylate several components of the 
complement system, such as C3, C5 and C9, causing the subsequent inhibition of 
classic and alternative complement pathways (Sher, 2002). 
 
1.3.2 Acquired Immune Response 
The mammal immune response is an important barrier that can prevent the 
establishment of a long-lasting chronic infection. Macrophages play an important role in 
the initiation, modulation and regulation of the acquired immune response since they 







 Antigen Presentation 
There are three cells recognized as professional antigen presenting cells (APCs): MØ, 
dendritic cells (DCs) and B lymphocytes. However, only MØ are simultaneously the 
Leishmania definitive host cell and APC. 
Differentiated from bone marrow precursor cells, bloodstream monocytes can migrate 
through the blood vessel and settle in the tissues as mature MØ, constituting the 
mononuclear phagocyte system (Roitt et al., 2006; Duque and Descoteaux, 2014).   
Macrophages recognize and phagocyte pathogens, process the antigens and present the 
complex antigen - MHCII to T helper cells, resulting in T lymphocyte activation, and 
the consequent release of cytokines than can activate other cells like B cells.  Activated 
B lymphocytes initiate the production of antibodies specific to the antigens presented by 
MØ (Duque and Descoteaux, 2014). 
MHC molecules synthesized in the APCs endoplasmic reticulum are conducted along 
the Golgi complex, subsequently transported to endosomes / lysosomes toward the 
plasma membrane. 
According with Germain and Margulies (1994) there are two principal ways to complex 
with the antigen. MHCI bound to peptides, which are broken down within the cell and 
transported to the endoplasmic reticulum. While peptides derived from the extracellular 
proteins are related to MHCII molecules. Peptides resulting from proteins that have 
been internalized by the cell and then degraded in phagolysosomes are transferred to a 
vesicle called MIIC which binds to MHCII. The MHCII-peptide complex moves to the 
cell surface, indicating the existence of intracellular infection. The T helper cell 
(TCD4
+
) interact with antigen presenting molecules, triggering an appropriate immune 
response (Roitt et al. 2006). 
For the interaction between MØ and T cells have the right conformational stability 
required to drive lymphocyte activation, the additional intervention of several types of 
molecules, such as co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86), present on 
the surface of APCs and recognized by receptors CD28 (positive co-stimulatory signal) 
and CD152 (CTLA-4) (negative co-stimulatory signal) on the surface of T cells are 
crucial (Santos-Gomes et al., 2008).  
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The modulation of T cell functional activity is another mechanism that allows the 
parasite to evade the host immune response. Several in vitro studies with infected MØ 
showed that amastigote forms of Leishmania lead to a MHCII decrease in the MØ 
surface (Reiner et al., 1987; Kwan et al., 1992). Furthermore, these parasites prevent the 
access of MHCII to parasite antigens, promoting the internalization and degradation (L. 
amazonensis) of MHCII molecules inside the parasitophorous vacuole (Leao et al., 
1995). Several assays with different parasites, L. major, L. donovani and L. 
amazonensis, also showed inhibition of antigen processing and binding to MHC 
molecules, as well as the retention of parasite antigens in the endocytic compartments 
(Kima et al., 1996; Bogdan and Röllinghoff, 1999; Zambrano-Villa et al., 2002). 
Using these mechanisms, the parasite subverts the activity of host acquired immune 
response, increasing their own ability to survive.  
Mature T lymphocytes, also express CD8 molecules, which are important to monitor all 
the cells of the body and control viral infections. Once active,CD8
+
 cytotoxic T 
lymphocytes (CTLs) recognize antigen presented by MHC class I and can rapidly kill 
the infected cell considered to be a threat to the integrity of the host. Moreover, CTLs 
have the ability to identified quantitative and qualitative antigenic differences in 
transformed cells, eliminating spontaneous malignant tumors (Andersen et al., 2006, 
Roitt et al., 2006). 
 
 
 Induction of a lymphocyte activation 
TThe resistance or susceptibility to Leishmania infection depends on the ability of T 
lymphocytes to specifically proliferate. After stimulation, CD4
+
 T cells can differ 
functionally in two sub-populations, T helper 1 (Th1) and T helper 2 (Th2), which 
produce a particular blend of cytokines Th1-type response, a protective immune 
response, is associated with the production of proinflammatory cytokines, such as 
interferon (IFN)- that induces the production of nitric oxide (NO) by MØ, promoting 
parasite killing (Green et al., 1991; Liu and Uzonna, 2012). However, other cells are 
involved in cytokine production, DCs produce IL-12 and natural killer cells (NK) also 
produce IFNSacks and Noben-Trauth, 2002; Teixeira et al., 2006). While the 
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cytokines IL-4, IL-5 and IL-10 are typical of a Th2 type immune response, stimulating 
the antibody production by B cells (Mosmann and Coffman, 1989; Sacks and Noben-
Trauth, 2002; Duque and Descoteaux, 2014).  The prevalence of Th2 non-protective 
immune response in a Leishmania infection is associated with disease severity (Heinzel 
et al., 1989; Reiner and Locksley, 1995) and supports parasite persistence. 
 
 Macrophage extracellular traps 
 
In addition to the production of oxidative radicals, MØ also have other mechanisms to 
combat Leishmania parasites. As a multifunctional cell, MØ are able to emit 
extracellular chromatin webs, known as macrophage extracellular traps (METs) (Chow 
et al., 2010; Boe et al., 2015).These traps are considered to be an antimicrobial strategy 
used to entrap and kill a wide spectrum of microbial organisms, protozoan included 
(Goldmann and Medina, 2012; Mohanan et al., 2013). Beside chromatin, METs are also 
constituted by nuclear DNA, histones, antimicrobial peptides and proteases (Boe et al., 
2015). 
MØ stimulated by lipopolysaccharide (LPS), cytokines, such as IL-8 and tumoral 
necrosis factor (TNF-α) and chemicals, as is the case of phorbol myristate acetate 
(PMA) present chromatin decondensation followed by the mix up of euchromatin and 
heterochromatin and disruption of the nuclear membrane, losing the cell the normal 
organized configuration/morphology. Generation of vesicles in the nuclear and 
cytoplasmic membrane ends with release of DNA fibers into the extracellular 
environment (Goldmann and Medina, 2012; Mohanan et al., 2013; Boe et al., 2015). 
Although the production of radical oxidative specimens (ROS) and the activity of 
NADPH oxidase are essential for the release of extracellular traps (ET) it has been 
reported that microorganisms like Staphylococcus aureus and L. donovani induce ET 
release through a molecular process that is independent of ROS (Goldmann and 
Medina, 2012). 
Extracellular traps are a different process of cell death, morphologically and 





1.4. Diagnostic Methods 
 
Ultimately, the diagnosis of leishmaniasis is considered positive when amastigotes are 
detected in relevant tissue aspirates, as bone marrow and lymph nodes or biopsies of 
skin lesions in the case of LV or LC, respectively.  
There are basically three types of diagnostic methods: parasitological methods (parasite 
detection), seroimmunological methods (detection of anti-Leishmania antibodies) and 
molecular methods for detecting parasite DNA. 
  
1.4.1. Parasitological Methods 
Parasitological methods allow parasite direct examination or parasite isolation in culture 
media.  
Direct examination under the optical microscope of Giemsa stain smears of proper 
biological samples allows the amastigote visualization (Kilic et al. 2008). Although this 
method presents a high specificity its sensitivity is mostly depending on infection 
intensity (Harith et al. 1987). 
Cultural examination is the conventional parasitological method. Classically, the 
biological sample is inoculated into the biphasic blood/agar “Novy-MacNeal-Nicolle” 
(NNN) medium. However, other commercial growth liquid media supplemented with 
bovine sera can also be used. However, this is a time-consuming method that exhibit 
reduced sensitivity in the initial stage of the disease, when parasite levels are low. As the 
media used to grow Leishmania parasites are rich in nutrients, the lack of care during 
the entire process can lead to contamination by other microorganisms, such as fungi and 









1.4.2. Seroimmunological Methods 
Among the seroimmunological methods used in VL stands out the indirect 
immunofluorescence (IFI), the enzyme-linked immunosorbent assay (ELISA), the direct 
agglutination test (DAT) and the immunochromatographic test rK39 (Alvar et al. 1997; 
Desjeux, 2004; Maia and Campino, 2008). However, most of the serological methods 
used in leishmaniasis diagnosis do not allow the distinction between the past and the 
recent infections. Moreover, these tests are not reliable in immunocompromised patients 
(Piarrouxet al., 1995). 
 
1.4.3. Molecular Diagnostic 
Despite the aforementioned diagnostic techniques are often used in the laboratory, none 
of them is completely satisfactory. Looking for simplest procedure, high sensitivity and 
specificity, faster and non-invasive diagnostic method makes PCR one of the 
alternatives to the traditional diagnostic techniques. PCR based methodologies are 
increasingly used and accepted as a diagnostic method, since it detects parasite DNA in 
a wide variety of samples and in all clinical forms of the disease (Minodieret et al. 
1997; Schallig and Oskam, 2002). 
 
1.5. Treatment 
Leishmaniasis treatment is complex and depends upon the clinical syndrome and the 
causative organism. However, there are only few specific anti-leishmanial drugs and the 
treatment exhibits several disadvantages such as high costs, same drugs used must be 
given parenterally, high toxicity and eventual development of drug resistance (Croft et 
al., 2006; Singh et al., 2012). 
 
Antimonials 
The first-line drugs for the treatment against all forms of leishmaniasis, which stands for 
more than 70 years are the pentavalent antimonial compounds (Sbv) sodium 
stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®) (Singh et al., 
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2012; Farrar et al., 2014). Currently, these compounds are still being considered as the 
first-line antileishmanial drugs in countries of South America, North Africa, Middle 
Eastland also in some European countries (Gradoni et al., 2008). These drugs inhibit 
parasite metabolic enzymes by blocking the generation of guanosine triphosphate (GTP) 
and adenosine triphosphate (ATP), the energy required for the processes that allow the 
survival of the parasite, as well as the pyruvate dehydrogenase and also trypanothion 
reductases, whose importance for the parasite is crucial in protection against host 
reactive oxygen and nitrogen species (Singh et al., 2012). 
Significant drug resistance can be explained by inappropriate use, as in the case of sub-
therapeutic doses that allow the parasite to develop tolerance to the drug or the use of 
drugs of poor quality manufacture (Sundar, 2001; Croft et al., 2006). 
Amphotericin B (AmB) 
Amphotericin B is a natural antibiotic with antifungal and anti-parasitic activity first 
isolated from Streptomyces nodosus. This aromatic diamine binds irreversibly to 
ergosterols in the membrane of Leishmania parasites, causing pores that leak ions, 
promoting the subsequent cell death (No, 2016). AmB is mostly used in resistant cases 
of leishmaniasis as a second-line drug, but severe adverse effects may also occur, since 
a prolonged period of treatment is required. The liposomal formulation of AmB 
(AmBisome ®) presents a high efficacy in short-course regimens and has fewer 
secondary effects, but the high cost and the parenteral administration are the main 
disadvantages (Sundar et al., 2001; Murray et al. 2005; Farrar et al., 2014). 
 
Miltefosine(MILT) 
Miltefosine initially developed in the 1980s as an anticancer drug has been used as 
orally effective anti-leishmanial agent. Although the mechanism of action is unclear, it 
seems to be related to alterations in the lipid metabolism, inducing the change of 
phospholipid metabolism and causing pathogen apoptosis. Although there are serious 
inconveniences, this drug requires a long period of administration with adverse effects, 
including vomiting and diarrhea with occasional hepatic and renal toxicity, which can 
lead to the abandonment of treatment and therefore low patient compliance. In addition 
to the fact that it is a highly teratogenic drug, MILT it is not suitable for pregnant 
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women (Sundar et al., 2012; Singh et al., 2012; No, 2016). Another disadvantage of this 
drug is the long half-life, so its use in monotherapy should be avoided in order to 
prevent the emergence of resistance (Croft et al., 2006; Farrar et al., 2014). 
 
Pentamidine  
This aromatic diamidina was the first drug to be used in refractory patients following 
treatment with the antimonial. However, this drug has been abandoned in the treatment 
of human LV due to the progressive declined rate of treatment failure, their high toxicity 
and cost (Murray, 2005; Croft et al.,2006; No, 2016). 
 
1.6. New approaches 
Several other classes of drugs have been tested in order to improve antileishmanial 
therapy, including lower toxicity, greater effectiveness and low cost (Sundar et al., 
2001; Jesus et al., 2015). Several plant compounds have shown a therapeutic effect 
against Leishmania such as alkaloids; particularly indoles, naphtylisoquinolines, 
bisbenzylisoquinolines, benzoquinolizidines; the terpenoids, including the triterpenes, 
steroids, saponins, sesquiterpenes and diterpenes; and the flavonoids, including several 
chalconas and isoflavones (Passero et al., 2013). 
Notably, two of the most important triterpenoid compounds, oleanolic acid and ursolic 
acid exhibit a broad spectrum of antifungal activity (Liu, 1995). As well as 
leishmanicidal activity against L. amazonensis and L. braziliensis (Passero et al., 2011), 
L. donovani, L. major (Begum et al., 2014) and L. infantum (Musayeib et al., 2013) 
promastigotes. Triterpenoid compounds present similar therapeutic effect as AmB, 
associated with moderated cytotoxic effects. These drugs are being strongly considered 
as an alternative treatment for the disease (Passero et al., 2011; Yamamoto et al., 2014). 
Others compounds to be taken into account are the flavonoids quercetin and chalcone 8. 
Both these drugs have revealed important advantages in the treatment of leishmaniasis 
when compared with the current drugs. For example, quercetin was able to control 
lesion size in L. amazonensis-infected mice, having similar effects as glucantime 
(Passero et al., 2013). Also, synthetic chalcone analogs showed high activity against 
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intracellular L. infantum and L. braziliensis (Mello et al., 2014), and in some cases 
proved to be more effective than Pentostam, the reference drug used (Boeck et al., 
2006). 
Take into account the above considerations, the experimental compounds are strongly 

























The immune system is crucial as a host defense against a variety of pathogens. 
However, Leishmania parasites preferentially infect MØ. These cells have a key role in 
the immune system and are involved in both innate and cell-mediated immunity. 
Therefore, this study aims to characterize the activity of human MØ when exposed to 
visceral and cutaneous species of Leishmania spp. 
Using L. infantum, L. amazonensis, L. shawi and L. guyanesis parasites, the following 
specific goals were taken into account: 
1. Differentiate MØ from monocytes and isolate lymphocytes from peripheral 
blood of healthy adults; 
2. Characterize in vitro MØ infection by optical microscopy; 
3. Assess  MØ activation by: 
3.1. Examine MØ morphological changes, including METs emission  
through  scanning electron microscopy and fluorescence microscopy; 
3.2. Analyze the production of nitric oxide by Griess reaction; 






3. Material and methods 
3.1. Experimental design (flowchart) 
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Macrophages: Analyzed by  flow 
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         L. amazonensis  
          L. shawi  
                   L. guyanensis  
Production of nitric 
oxide 
MHC I+ and MHC II+ 
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expression 
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3.2. Biological samples 
For this study, peripheral blood samples were obtained from healthy volunteers of both 
genera, over 18 years of age and actually living in Portugal. The participants were 
informed of the objectives of the study and approved consents were obtained.  Assays 
were performed in, at least 10 volunteers and the direct agglutination test (DAT) was 
applied to identify a possible previews contact with L. infantum. 
 
3.2.1. Mononuclear cells 
Mononuclear cells (lymphocytes and monocytes) were obtained following a simple 
method according with Bøyum (1976). This method takes advantage of density 
differences between mononuclear cells and other cellular constituents (red cells and 
PMN).  Hystopaque® (density 1.077 g.mL
-1
, Sigma-Aldrich), a solution of polysucrose 
and sodium diatrizoate, was used to create a density gradient.  
The blood sample was collected into 50 mL tubes with the anticoagulant citrate-
phosphate dextrose adenine (CPD-1) (Polymed). In a 15 mL tube were placed 3 mL of 
Hystopaque and carefully layered on the same quantity of blood, avoiding any mixture. 
The tubes were centrifuged at 425 ×g, 20 min at room temperature with no brake. 
Differential migration during centrifugation results in the formation of layers of 
different constitution. Erythrocytes are aggregated by polysucrose and rapidly sediment, 
granulocytes become slightly hypertonic, which increases their sedimentation rate, 
resulting in pelleting at the bottom of the centrifuge tube. Mononuclear cells and 
lymphocytes (PMBC - peripheral blood mononuclear cells), which have a lower density 
than the other cells are found at the interface between the plasma and the Hystopaque 
constituting a white layer (Figure3.1). The layer was gently removed using a Pasteur 
pipette and washed three times (300 ×g for 10 min at room temperature) in phosphate 
buffered saline (PBS) to remove the excess of Hystopaque. Cells were then resuspended 
in RPMI 1640 (Lonza) at pH 7.2 supplemented with 2 mM L-glutamine (Merck), 100 
μg.mL
-1
 of streptomycin (Sigma-Aldrich) (complete RPMI 1640 medium), 10% (v/v) of 
heat-inactivated fetal bovine serum (FBS) (BioWhittaker) and 20% (v/v) of colony 
stimulating factor (CSF) to induce monocyte differentiation into MØ.  Concentration of 
viable cells was assessed by trypan blue staining method. This dye enters passively into 
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non-viable cells that stain blue while viable cells can actively exclude the dye. 
Concentration of viable cells was estimated in a Neubauer-counting chamber under 
optical microscope (OM). The plasma was also collected into a dry tube and stored at -
20ºC until be used. 
 
Figure 3.1. Isolation of blood peripheral mononuclear cells by density gradient. After centrifugation 
on the hystopaque ® gradient the ring of  monocuclear cells, enriched in lymphocytes can be visualized. 
3.2.2. Direct agglutination test 
Harith et al. (1986) developed an agglutination test (DAT) that can be used in large 
scale, easy to perform, read and interpret. When compared with other serologic tests, 
presents high levels of sensitivity and specificity and does not require any major 




The agglutination reaction detects L. infantum specific antibodies. In a positive control, 
the antigen forms a pale blue film over the well, but if the result is negative, antigen 
accumulates at the bottom of the plate, forming a dark blue spot. After an incubation 
period, the result is expressed as the highest dilution in which agglutination occurs. 
Using a 96 well V-bottom, 50 L of diluent solution previous prepared [0.15 M HCL, 
with 0.2% gelatin (Sigma-Aldrich) in distilled water and 0.2 M 2-mercaptoetanol 
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(Sigma-Aldrich)] were plated in the wells. Plasma samples (50 L) were added to the 
first column and 1:10 serial dilutions were made. For negative control were use wells 
without plasma. Serum samples from individuals with visceral leishmaniasis kindly 
provided by Prof. Carlos Henrique Nery Costa from the Federal University of Piauí, 
Teresina, Brazil, were used as positive controls. The antigen used was gently provided 
by Prof. Saul Semião Santos, Tiradentes University, Aracaju, Brazil. Then, the plates 
were incubated for 1 h at 37ºC and 50 L of antigen (5 μg.mL
-1
) were added to each 
well. Plates were incubated overnight at room temperature. The results were assessed 
visually, and are expressed as the maximum dilution at which agglutination is observed.  
 
3.2.3. Flow cytometry 
Flow cytometry is a technique widely used to analyze multiple characteristics of single 
particles in a fluid. This method allows the individual analysis of cellular multiple 
characteristics, such as size (represented by forward-angle light scatter), internal 
complexity (represented by right-angle scatter), and the immunophenotyping by 
evaluating the expression of intracellular and cell surface markers, using specific 
monoclonal antibodies complexed with fluorescent reagents (fluorochroms) (Figure 
3.2). 
 
Figure 3.2. Schematic representation of flow cytometry process. Cell can be evaluated by forward 
scatter (FSC), which is proportional to the cell surface area or size (A) and by side scatter (SSC) that is  
proportional to the degree of internal complexity of the cell. Plotted results show different leukocyte 




In the flow cytometer (Figure 3.3), each cell flowing in a liquid stream is intercepted by 
a laser light and fluorochromes release fluoresce in all directions. Optics direct the light 
to series of beam splitters and filters to appropriate detectors. The electronic signals 
produced are digitized for computer analysis (Brown and Wittwer, 2000). Since 
fluorochromes can have extended emission curves, different light wavelengths can be 
simultaneously scattered from one cell. When the emission curves overlap the proper 
data analysis become affected. Thus, spectral compensations obtained by subtracting a 
percentage of signal from one detector to the other and aligning populations affected by 
spillover are a very important way to solve this issue.   
 
Figure 3.3. The principal components of a flow cytometer: The flow system includes the fluidics, optical system, 
light sensing, electronic system and the signal processing. https://www.labome.com/method/Flow-Cytometry-A-
Survey-and-the-Basics.html 
3.2.4. Peripheral blood monocyte differentiate macrophage 
Monocytes circulate in the bloodstream until migrated to other tissues, differentiating 
into MØ able to develop and execute specialized functions. In order to maximize the 
number of MØin culture, it was necessary to determine the best incubation time. 
In a six wells plate, 3 mL of monocyte suspension (described in 3.2.1) was seeded per 
well and the plates were incubated in an incubator  at 37 ºC ± 1 ºC, with 5% CO2 in a 
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humidified atmosphere. At different time points (24 h, 48 h and 72 h) obtained samples 
were acquired by flow cytometry. 
Macrophages are cells with ability to adhere to a substrate as is the case of polyethylene 
terephthalate, depositing on the bottom of the plate. At each time point, cells were 
washed with 0.9% NaCl and removed by thermal shock (30 min on the ice) using a 
sterilized cell scraper (VWR) in a gentle way to ensure the integrity of plasmatic 
membrane.  
The cell suspension was centrifuged (300 ×g for 10 min at room temperature) and the 
pellet was resuspended in 500 µl of 2% paraformaldehyde, and then set on ice for 20 
min protected from light. Cells were then washed (400 ×g, for 10 min at + 4 ºC), the 
supernatant were rejected and the pellet resuspend in 500 µl of PBS 1×. Cells were kept 
in the dark at + 4 ºC until be analyzed by flow cytometry.  
 
3.2.5. Isolation of lymphocytes 
As previously mentioned (3.2.4) MØ adhere to polyethylene terephthalate, so it is 
possible to isolate lymphocytes, non-adherent cells (supernatant), after 24 h of 
incubation time.  
The cellular suspention was centrifuged at 300 ×g for 10 min at room temperature. Then 
re-suspended in complete RPMI 1640 medium supplemented with 10% (v/v) FBS and 
1% of DMSO and preserved at -20 ºC until be used.   
 
3.3. Parasites 
Four species of Leishmania were used in the present study. The visceral L. infantum 
(MCAN/2012/IHMT0003SG) isolated from a case of canine leishmaniasis (LCan) from 
Seixal municipality (Setúbal, Portugal) and maintained in BALB/c mice by successive 
passages. To assure the use of virulent parasites, only L. infantum promastigotes with 
less than five passages in culture (Santos-Gomes and Abranches, 1996) was used 
throughout the study. 
Cutaneous strains of Leishmania were kindly provided by Dr.  Luiz Felipe Passero. L. 
amazonensis (MHOM/BR/1973/M2269) was isolated from a patient presenting anergic 
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diffuse leishmaniasis, living in Pará state (Brazil). L. shawi (MHOM/BR/96/M15789) 
was isolated from a patient with LC from Buriticupu (Maranhão state, Brazil) and L. 
guyanensis (MHOM/BR/2001/M19663) was isolated from a patient with LCL, living in 
Santarém (Pará state, Brazil). The parasites were maintained in BALB/c mice, being 
subsequently isolated from lesions on the footpads. Parasite identification was based on 
monoclonal antibodies and multilocus enzyme electrophoresis at the Evandro Chagas 
Institute (Passero et al., 2012).  
Parasites were cultured in Schneider's Insect Medium (SCHN, Sigma-Aldrich) 
supplemented with 10% FBS and penicillin-streptomycin (Biochrom, Germany) at 100 
U.mL
-1
 and 100 µg.mL
-1
 respectively (complete SCHN medium), and incubated at 24ºC 
± 1 °C in a refrigerated incubator (Lovibond, Germany). Concentration of promastigotes 
in culture (promastigotes.mL
-1
) was determined under OM using a Neubauer-counting 
chamber and calculated according to the following equation: 
 





n= total number of promastigotes counted 
50=factor associated with the number of squares counted 
FD =Dilution factor 
   =Volume correction factor 
This equation was adapted for counting on the central square of Neubauer-counting 
chamber. 
 
3.3.1. Macrophage Infection 
In a chamber slide (LabteK Chamber Slide
TM
, Nunc) was added 300 L of cell 
suspension in complete RPMI medium supplemented with 20% (v/v) CSF and 10% 
(v/v) FBS. Every day the culture medium was replaced with fresh medium until MØ 
achieved complete differentiation on the 3th day of culture. Cells                  ) 
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were then exposed to  L. amazonensis, L. guyanensis, L. shawi or L. infantum 
promastigotes at MØ/parasite ratio of 1:5. After 5 h at 37°C in a 5% CO2 humidified 
atmosphere, cells were washed with PBS 1× to remove non internalized free 
promastigotes. Plastic chamber was detached from slide and left to dry. Slides were 
fixed with methanol and stained with Giemsa. The amount of infected cells (i.e. number 
of infected cells per 100 MØ) and the intensity of infection (i.e. number of amastigotes 
per infected cells) were determined by light microscopy at ×1000 magnification by 




3.3.2.1. Scanning electron microscopy 
As scanning electron microscope (SEM) uses a focused beam of high-energy electrons 
to interact with the solid surface of the sample, generating high resolution 2D-images. 
In the present study, SEM was used to evaluate the ability of Leishmania spp. to induce 
MET release.  
Samples for SEM were prepared according to Brinkmann et al. (2010).  
In a 24-well cell plate,  sterile glass cover slip was placed and                   
plated. Then   L. amazonensis, L. guyanensis, L. shawi or L. infantum promastigotes 
were added at macrophage/parasite ratio of 1:5. In parallel, LPS-stimulated MØ PMA-
stimulated MØ and PMA-stimulated MØ exposed to Leishmania spp. were used as 
positive controls. After 5 h at 37°C in a 5% CO2 humidified atmosphere, the coverslips 
were fixed with 2.5 % glutaraldehyde (Sigma-Aldrich). 
Later on, coverslips were washed three times with water and transferred to new 24 plate 
with 0.5% osmium tetroxide (OsO4, Sigma-Aldrich) and incubated for 30 min at room 
temperature.  Water washing steps were realized before 30 min of incubation at room 
temperature with 1% tannic acid (Sigma-Aldrich). Slides were then submitted to new 
washing, incubated again with 0.5% OsO4 solution and washed again. Cells were then 
dehydrated by successive passages in increasing concentrations of ethanol (30%, 50%, 
70%, 80%, 90% and 100%) and conserved at +4ºC in 100% ethanol. At last, samples 
were dried by using the critical point drying method and metallized with gold 
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3.3.2.2. Histone detection by immunolabeling 
Immunolabeling is a biochemical process that enables the detection and localization of 
an antigen in a particular site within a cell. In the present study immunolabeling was 
used to localize histone during macrophage infection and treatment. 
For this procedure, after the coverslips being fixed in the well with 2.5% glutaraldehyde 
(as described in 3.3.2.1.), cells were washed three times with PBS 1× and permeabilized 
using 0.5% Triton X-100 (Sigma-Aldrich). Then, coverslips were washed again (PBS 
1×) and transferred to new 24 well plate with blocking buffer. The plate was incubated 
in a humid chamber for 30 min at 37ºC. After incubation, cells were stained with the 
primary antibody Histone H1 (AE-4, Santa Cruz Biotechnology, Germany) diluted in 
blocking buffer and incubated (1 h, 37ºC). The coverslips were submitted to a new 
washing and the secondary antibody goat anti-mouse IgG (Santa Cruz Biotechnology, 
Germany) was added.  Cells were incubated for 1 h at 37ºC, washed and stained with 
DAPI (4',6-diamidino-2-phenylindole) (Sigma-Aldrich). DAPI is a fluorescent dye that 
strongly binds to the A-T regions of DNA and can be used to stain both live and fixed 
cells. The slides were maintained in the dark at + 4 ºC until be analyzed by fluorescence 
microscopy. 
 
3.3.3. Production of nitric oxide by macrophages 
In general, infected Ø can produce nitric oxide (NO). NO is generated by inducible 
NO synthase (iNOS), an enzyme that catalyzes the oxidation of L-arginine in NO and 
L-citrulline. 
Supernatants of resting-MØ, PMA-stimulated MØ and MØ exposed to Leishmania 
promastigotes for 5 h were used to quantify total nitrate plus nitrite by Nitrate/Nitrite 
Colorimetric Assay Kit (Abnova, Taiwan).  
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This method converts the ion NO3
-
 present in the supernatants to ion NO2
- 
by the 
enzyme nitrate reductase. Subsequent addition of Griess reagent converts NO2
-
 in to azo 
chromophore pink/purple compound, allowing the determination of total concentration 
of both metabolites in the sample. 
The assay was made according to the manufacturer’s instructions without sample 
dilution. A standard curve was built to estimate the concentration of the metabolites in 
the sample, by reading the absorbance of known NO3 amounts (final concentrations 
between 35 M and 5 M). Absorbance was measured at 550 nm using a microplate 
reader (Anthos 2010, Austria). 
 
3.3.4. Evaluation of MHC in infected-MØ when in contact with 
lymphocytes 
Lymphocytes, previously isolated were added to homologue infected-MØ and incubated 
for 20 h at 37 ºC in a 5% CO2 humidified atmosphere. The cells were removed  
according with 3.2.4. Then, the cell suspension was centrifuged (300 ×g for 10 min at 
room temperature) and the pellet was resuspended in 500 µl of PBS 1×. Cell 
suspensions were equally divided into two 2 mL Eppendorf  tubes (DeltaLab),the first 
one, stained with APC anti-human HLA-A,B,C (BioLegend) and the other, FITC anti-
human HLA-DR, DP, DQ (BioLegend). Then, cells were set on ice for 20 min protected 
from light. Cells were washed (400 ×g, for 10 min at + 4 ºC), the supernatant was 
rejected and the pellet was resuspend in 500 µl of 2% paraformaldehyde. Afterwards,  
cells were set on ice for 20 min and protected from light. At the end, one more wash 
was made, and the pellet was resuspend in 500 µl of PBS 1× and cells were kept in the 
dark at + 4 ºC until be analyzed by flow cytometry (Cytoflex, Beckman coulter life 







3.3.5. Statistical analysis 
Statistical analysis was performed with the IBM SPSS Statistics version 
23.0 (IBM, USA).The non-parametric Wilcoxon test was used to compare variables of 
two dependent samples from 10 samples of Leishmania-infected macrophages evaluated 






















4. Results and Discussion 
 
4.1. Participants did not evidence previous contact with L.  infantum 
parasites 
DAT was negative for all participants, evidencing no previous contact with L. infantum. 
These results indicate that the individuals that participated in this study, did not develop 
antibodies anti-L. infantum, suggesting that they were never infected.  
4.2. Macrophages 
4.2.1. Complete macrophage differentiation was achieved after 72h of 
incubation 
Macrophages derived from peripheral blood monocytes and are strategically located 
throughout lymphoid and non-lymphoid body tissues However, not only tissue MØare 
difficult to obtain as it is also hard to get in a high number to be used as a research tool.  
Thus, isolate monocytes from peripheral blood and differentiate into MØ is a way to 
overcome this barrier.  
After peripheral blood monocyte isolation (PBM) the period of time needed for MØ 
differentiation was established by flow cytometry analysis. Taken into account that MØ 
present higher forward (size) and side scatter (complexity) levels than monocytes, it was 
estimated a period of 72h for MØ achieve complete differentiation. Furthermore, 
morphologically these cells showed an extensive ruffled plasma membrane and a large 
purple-stained nucleus, presenting an irregular shape (Figure 4.1) characteristic of MØ 
and, also exhibited the phagocytic ability. Consequently, further assays were performed 





Figure 4.1. Macrophages differentiation. Peripheral blood monocytes were left to differentiate into MØ 
in the presence of CSF. Forward Scatter (x axis) VS Side Scatter (y axis) dot plots generated at 24 h, 48 h 
and 72 h of culture are showing. The selected area R1 correspond to monocytes, R2 to other smaller and 
less complex cells and R3 correspond to fully differentiate MØ. After 72 h of differentiation, cells were 
stained with Giemsa and observed by optical microscopy. Acquired images (× 1000 magnification, scale 
bar corresponds to 10 µm) exhibit cells with morphological characteristics of macrophages (A). 
 
 
4.2.2. Cutaneous species of Leishmania show high infectivity to human 
macrophages 
The percentage of MØ infected with Leishmania parasites and the number of 
intracellular parasites per macrophage using the macrophage : parasite proportions of 
1:5 for 5 h of incubation time was determined by morphological evaluation under 






































Figure 4.2. Macrophages infected with Leishmania spp. Macrophages were exposed to promastigotes 
of L. amazonensis (LA), L. infantum (LI), L. shawi (LS) and L. guyanensis (LG) at a MØ/parasite ratio of 
1:5 for 5h. The percentage of MØ infected was determined by light microscopy (× 1000 magnification) 
by counting at least 100 cells per well in slides stained with Giemsa. The results are expressed as standard 
deviation of ten samples. *(p<0.05) indicates statistical differences between LI and  the cutaneous 
species. 
  
The percentage of cells infected with cutaneous species have a higher rate in 
comparison to the visceral species(p=0.0286). L. infantum had no more than 43%. This 
result was similar to the percentage of human PBM infected with L. infantum 
promastigotes obtained by Ogunkolade et al. (1990) and to the human PBM infected 
with Leishmania strains (IMT-151/ IMT-373) obtained by Maia et al. (2007). 
And clearly, L. amazonensis is the species with the highest rate of infection (89%), 
followed by L. shawi (78%) and L. guyanesis (74%). Similar results were obtained for 
Campos et al. (2008) in both strains (L. shawi and L. guyanesis), although significant 
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Figure 4.3. Intensity of macrophage infection caused by Leishmania spp. Macrophages were exposed 
to promastigotes of L. amazonensis (LA), L. infantum (LI), L. shawi (LS) and L. guyanensis (LG) at a  
MØ/parasite ratio of 1:5. The number of intracellular amastigotes per 100 cells (A) was determined at 5 h 
post infection by light microscopy (× 1000 magnification) in slides stained with Giemsa. The results are 
expressed as the mean and standard deviation of ten samples. * (p<0.05) indicates statistical differences 
between LI and  the cutaneous species. Optical microscopy images of macrophages showing intracellular 
amastigotes of L .amazonensis (A), L. shawi (B) and of L. guyanensis (C) were also acquired. 
 
The number of amastigotes present in the cells for each strain intensifies the infection 
rates. Once again, L. infantum have the lowest value (median = 58 amastigotes), 
showing less permissiveness(p=0.0286), in contrast with L. amazonensis (median = 428 
amastigotes), intermediate values for L. shawi (median = 264 amastigotes) and L. 








4.2.3. Leishmania spp. do not promote macrophage oxidative burst 
The production of nitric oxide (NO) by the enzyme NO synthetize (iNOS) is one of 
mechanism used by MØ to destroy parasites that can be induced by cytokines and other 
immune stimuli. However, it has been reported that Leishmania spp. inhibit macrophage 
NOS2expression (Bogdan et al., 2000). NO production by MØ exposed to visceral and 












Figure 4.4. Nitric oxide production by macrophage exposed to Leishmania spp. Supernatants of 
blood monocyte derived macrophages  incubated with  promastigotes of L. amazonensis (LA), L. 
infantum (LI), L. shawi (LS) and L. guyanensis (LG) at a MØ/parasite ratio of 1:5 for 5h were used to 
evaluate NO release. In parallel, supernatants of resting MØ  and of PMA-stimulated MØ  were also 
assessed. *(p<0.05) indicate statistical differences between LI and other conditions.  
 
 
It was possible to detect the presence of NO in the infected MØ, and as expected these 
results were low because Leishmania spp. inhibits the NO production in the infected 
cells, facilitate the initial survival of the parasites in the host, significant differences 
were not found. Leishmania infatum was the species that caused higher inhibition of 
MØ oxidative burst (p=0.0148). 
 























4.2.4. When in contact with lymphocytes Leishmania spp. stimulates 
MHC expression 
The vertebrate hosts have a set of molecules that bind to antigenic peptides, to be 
recognized by the immune system, these molecules are part of the MHC. Although 
macrophages are professional APC able to process non-self antigens and present it by 
complexing with MHCII, these cells can also present antigens to MHCI.  To compare 
the ability of macrophages infected  with different species of Leishmania  to present 
parasite antigens when in presence of lymphocytes, the expression of MHC molecules 
were evaluated by flow cytometry (Figure 4.5 and 4.6). Resting - MØ  were used to gate 
MHCI positive population  (Figure 4.5A). 
 
 
Figure 4.5. Frequency of Leishmania-infected MØ expressing MHCI when in presence of 
lymphocytes. Blood monocyte derived macrophages incubated with promastigotes of L. amazonensis 
(LA), L. infantum (LI), L. shawi (LS) and L. guyanensis (LG) in co-culture with autologous lymphocytes 
were evaluated by flow cytometry. In parallel,  resting MØ and IFN and PMA-stimulated MØ were also 
assessed. After gating on MØ population based on forward scatter and side scatter characteristics, resting-
MØ were used to gate MHCI
+
MØ(A).The results are expressed as the median, maximum and minimum 
of then independent samples (B). The non-parametric Wilcoxon test was used to compare paired 





Figure 4.6. Frequency of Leishmania-infected MØ expressing MHCII when in presence of 
lymphocytes. Blood  monocyte derived macrophages  incubated with  promastigotes of L. amazonensis 
(LA), L. infantum (LI), L. shawi (LS) and L. guyanensis (LG) and co-cultured with autologous 
lymphocytes were evaluated by flow cytometry. In parallel,  resting MØ and IFN and PMA-stimulated 
MØ were also assessed. After gating on MØ population based on forward scatter and side scatter 
characteristics, resting-MØ were used to gate MHCII
+
MØ(A).The results are expressed as the median, 
maximum and minimum of then independent samples. The non-parametric Wilcoxon test was used to 
compare paired samples. **(p≤0.001) and *(p≤0.05) indicate statistical differences between MØ and the 
other conditions.  
 
Most of macrophages exposed to parasites, regardless the species, evidenced high 
expression of MHCI and of MHCII that were significantly different from non-infected  




 T cells. However, MHCII
+
 
MØ subpopulation were smaller than MHCI
+
MØ, indicating a higher activation of 
cytotoxic T cells. 
The median of fluorescent intensity reflects the level of MHC molecules on MØ 
surface. Infected MØ presented significant higher increase of MHCI (Figure 4.7B;    
p<0.001) and MHCII (Figure 4.7A; p=0.001) when compared with resting-MØ. 
Although MHCII presented the higher expression levels, MHCI showed the grater 





Figure 4.7. MHCII and MHCI surface expression of Leishmania-infected MØ when in the presence 
of autologous lymphocytes. Blood  monocyte derived MØ  incubated with  promastigotes of L. 
amazonensis (LA), L. infantum (LI), L. shawi (LS) and L. guyanensis (LG) and co-cultured with 
autologous lymphocytes were evaluated by flow cytometry and the intensity fluorescence median 
recorded. In parallel, resting MØ and IFN and PMA-stimulated MØ were also assessed. The results are 
expressed as the median, maximum and minimum of then independent samples. The non-parametric 
Wilcoxon test was used to compare paired samples. ***(p≤0.0001), **(p<0.001) indicate statistical 
significant  differences between MØ and the other conditions.  
 
 
4.2.5. Leishmania infantum parasites downregulate MET emission 
The formation of MET by MØ have been, already, reported for RAW 264.7 
macrophage cell line upon PMA (Chow et al., 2010) and TNF-α stimulation (Mohanan 
et al., 2013). Liu et al. (2014) induced METs formation in murine peritoneal 
macrophages and J774A.1 in response to Escherichia coli and Candida albicans 
infection.  
 
In this study, MET formation was evaluated in Human macrophages differentiated from 





Figure 4.8. Leishmania infantum regulates the emission of MET by human MØ.  Blood  monocytes 
derived macrophages  were incubated with  promastigotes  (D)  were evaluated by scanning electron 
microscopy and images were acquired. In  parallel, non-stimulated  macrophages (A),  LPS-stimulated 
macrophages (B)  and  PMA-stimulated (C) macrophages were also evaluated. LPS and PMA-activated 
macrophages  show the release  of  web- and fiber-like  extracellular structures (I). Promastigotes are 
indicated by arrows. 
 
As expected SEM assays revealed that resting MØ (negative control) did not release 
MET. MØ chemical stimulated, LPS and PMA, showed MET formation and it is 
possible to identified spread and filamentous structures. It is possible to see the more 
interaction between MET and L. infantum promastigotes in cells stimulated with PMA. 
However, morphological changes were not so exuberant when compared with MET 
formation induced chemically, where was also perceived as large cloud-like structures, 
the spread of thin membranous veil and of filamentous structures MET-like, in 





4.2.7 Leishmania infantum parasites restrain the release of histone 
to the extracellular space 
Histones are small proteins constituents found in all eukaryotic cell nucleus. These 
proteins  package and order the DNA into structural units, nucleosomes. There are five 
major classes of histones. From these, H1is  the linker histone that binds to the 
nucleosome at the entry and exit DNA sites, thus locking the DNA into place and 
allowing the formation of higher order structure, chromantin. As previously stated, 
MET formation leads to nuclear disruption, releasing DNA fibers into the extracellular 
environment. 
Blood monocyte derived macrophages labeled with H1 histone were evaluated by 
fluorescent microscopy (Figure 4.8). 
 
Figure 4.9. Extracellular release of histone by human MØ. Blood  monocyte derived macrophages  
incubated with L. infantum promastigotes  (D)  and labeled with  H1 fitc and rodamine (green) were 
evaluated by fluorescent  microscopy and images were acquired. In  parallel, resting-macrophages, (A),  
LPS-stimulated macrophages (B)  and  PMA-stimulated macrophages (C)  were also evaluated. LPS and 
PMA-activated macrophages and parasites-exposed macrophages  show the extracellular release of H1. 




These results, once again, confirms the spread of nuclear structures outside the nucleus 
(Figure 4.9A) and into the extra cellular environment (Figure 4.9C) probably originating 
the formation of MET. Macrophages infected with L. infantum parasites promote the 
formation of MET, but in low amounts when compared with the stimulated MØ, 
suggesting a possible modulation of MET emission by L. infantum parasites. 
Antimicrobial activities of histones are already described in the literature against 
pathogenic organisms (Goldman et al., 2012). Therefore, further studies are needed to 

















4. Final remarks 
 
Macrophages are phagocytic cells of  innate immunity and antigen presenting cells, 
establishing the link between innate and acquired immunity. Simultaneously, these cells 
are also the definitive host cell of Leishmania parasites. Therefore, the present study 
evaluated the in vitro activity of blood monocyte differentiated human macrophages 
exposed to Leishmania spp. promastigotes. 
In general, the cutaneous species of Leishmania were more infective for blood 
monocyte differentiated macrophages than L. infantum. L. amazonesis parasites, which 
belong to Leishmania subgenus like L. infantum revealed higher infectivity.  
Leishmania parasites induce the expansion of  MHCI
+
MØ  subset and increase the 
MHCI expression at MØ surface, possibly driving  the differentiation of CD8
+
T cells 
able to induce the apoptosis of infected cells.  On the other hand, the population of  
MHCII
+
MØ and MHCII expression were less induced. This population should be able 
to enhance the activation of CD4
+
T cells that regulate further activation of cells of 
immune system, controlling  the infection. Despite the above considerations,  it seems 
that Leishmania parasites can modulate cell activation into some extension, promoting a 
balanced  immune response.  
Furthermore, L. infantum promastigotes also seem to induce some regulation in MET 
emission. Possibly,  eliminating the less virulent parasites, at the some time that assure 
the survival of the more virulent ones by privileging macrophage phagocytosis and 
parasite internalization. To the best of our knowledge, this is the first time that is 
described the induction of MET by L. infantum parasites. 
Further research are needed to complete understand the interaction of these parasites 
with the host immune response, leading to the development of efficient strategies to 
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